TuHURA Biosciences (NASDAQ:HURA) Rating Lowered to Sell at Wall Street Zen

Key Points

• Wall Street Zen downgraded TuHURA Biosciences (NASDAQ:HURA) from "Hold" to "Sell"; analyst views are mixed with Weiss rating "Sell" and HC Wainwright keeping a "Buy" with a $10 target, leaving a MarketBeat consensus of "Hold" and an average $9 price target.
• Shares trade near $1.45 with a $92.2M market cap and a 12‑month range of $0.41–$4.44; the company reported an EPS miss of ($0.13) vs. ($0.12) consensus.
• TuHURA is a clinical‑stage biotechnology firm focused on translating high‑dimensional proteomics into drug targets via a proprietary multiplexed protein‑profiling platform.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued on Tuesday.

A number of other equities analysts have also weighed in on HURA. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of TuHURA Biosciences in a research report on Thursday, January 22nd. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price target on shares of TuHURA Biosciences in a research report on Tuesday, February 3rd. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and an average price target of $9.00.

TuHURA Biosciences Price Performance

Shares of NASDAQ:HURA opened at $1.45 on Tuesday. The company's fifty day moving average price is $1.41 and its 200 day moving average price is $1.61. TuHURA Biosciences has a 12 month low of $0.41 and a 12 month high of $4.44. The firm has a market capitalization of $92.19 million, a P/E ratio of -2.30 and a beta of -0.32.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last issued its earnings results on Tuesday, March 31st. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01).

Institutional Trading of TuHURA Biosciences

Large investors have recently modified their holdings of the company. Bank of America Corp DE acquired a new stake in shares of TuHURA Biosciences during the fourth quarter worth approximately $59,000. Jane Street Group LLC acquired a new position in TuHURA Biosciences in the 1st quarter worth about $69,000. Geode Capital Management LLC increased its position in TuHURA Biosciences by 111.4% in the 2nd quarter. Geode Capital Management LLC now owns 582,992 shares of the company's stock worth $1,300,000 after purchasing an additional 307,260 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in TuHURA Biosciences in the 2nd quarter worth about $27,000. Finally, New York State Common Retirement Fund acquired a new position in TuHURA Biosciences in the 2nd quarter worth about $97,000. Institutional investors and hedge funds own 0.62% of the company's stock.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company's core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA's approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.